Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.jstrokecerebrovasdis.2020.104688

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Aortogenic embolic stroke (AES) is an important stroke mechanism. However, as many stroke patients have aortic atheromatous lesions, it is unclear whether these lesions are the cause of these strokes. Cholesterol crystals are the solid, crystalline form of cholesterol that is found in atherosclerosis, but not in cardiac diseases such as atrial fibrillation, valvular diseases, and cardiomyopathy. Therefore, if a cholesterol crystal is found in a thrombus removed by mechanical thrombectomy (MT), this makes it possible to diagnose a patient as having an atheromatous lesion. Here, we report an AES case with a cholesterol crystal found in a thrombus removed by MT. A 67-year-old man was admitted due to consciousness disturbance, aphasia, and right hemiplegia. Diffusion-weighted imaging (DWI) showed a hyperintense area in the left frontal lobe, and magnetic resonance angiography demonstrated a branch occlusion of the left middle cerebral artery (MCA). MT was performed 1.5 h after stroke onset, with the thrombus removed and a left occluded MCA completely recanalized. Carotid duplex ultrasonography did not reveal any plaque in the carotid artery. Echocardiography did not show any abnormal function or findings, including thrombus. Transesophageal echocardiography showed a 4.9 mm atheromatous lesion at the aortic arch. Therefore, we suspected this patient as having an AES due to the embolic source of atheromatous lesion at the aortic arch. Pathological examination of the embolus revealed a cholesterol crystal cleft in the thrombus. Therefore, we diagnosed this patient as having AES caused by an atheromatous lesion at the aortic arch.

DOI： 10.1016/j.jstrokecerebrovasdis.2020.105178

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本神経学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: We investigated the precise clinical and radiologic characteristics of intracerebral hemorrhage associated with direct oral anticoagulant use. METHODS: Patients with acute spontaneous intracerebral hemorrhage admitted to our department from September 2014 to November 2017 were retrospectively analyzed. Clinical and neuroradiological characteristics of patients with direct oral anticoagulant-related intracerebral hemorrhage, and effects of prior treatment on the severity at admission and on outcome at discharge were assessed. RESULTS: Of the 301 enrolled patients (103 women; median age 68 years), 261 received no oral anticoagulants (86.8%), 20 received warfarin (6.6%), and 20 received direct oral anticoagulants (DOACs) (6.6%). Median initial National Institutes of Health Stroke Scale scores differed significantly among the groups (P = .0283). Systolic blood pressure (P = .0031) and estimated glomerular filtration rate (P = .0019) were significantly lower in the oral anticoagulant-related intracerebral hemorrhage group than in other groups. Total small vessel disease scores were significantly higher in the oral anticoagulant-related intracerebral hemorrhage group than in the warfarin group (P = .0413). Multivariate analysis revealed that prior oral anticoagulant treatment (odds ratio: 0.21, 95% confidence interval: 0.05-0.96, P = .0445) was independently negatively associated with moderate-to-severe neurological severity (stroke scale score ≥10) after adjusting for intracerebral hemorrhage location and various risk factors. There were significant differences in hematoma volume in the basal ganglia (P = .0366). CONCLUSIONS: DOAC-related intracerebral hemorrhage may occur particularly in patients with a high risk of bleeding; however, they had a milder initial neurological severity than those with warfarin-related intracerebral hemorrhage, possibly due to relatively smaller hematoma volume, especially in the basal ganglia.

DOI： 10.1016/j.jstrokecerebrovasdis.2018.12.013

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Because the efficacy and safety of anticoagulant therapy in patients with acute intracerebral hemorrhage (ICH) are not fully known, present study aimed to elucidate the current status and the safety of anticoagulant therapy, mainly direct oral anticoagulants (DOACs), for acute ICH and anticoagulant-indicated patients. Methods and Results: From September 2014 through March 2017, consecutive patients with acute (<7 days from onset), spontaneous ICH were retrospectively enrolled from a prospective registry. Whether to start anticoagulation was at the attending physicians' discretion, and thromboembolic or hemorrhagic events during hospitalization were analyzed. A total of 236 patients (80 women [34%]; median age 69 [interquartile range 61-79] years; National Institutes of Health stroke scale score 7 [3-16]) were enrolled. Of them, 47 patients (20%) had an indication for anticoagulant therapy (33 had atrial fibrillation, 14 developed deep vein thrombosis), and 41 of 47 patients (87%) were actually treated with anticoagulant therapy (DOACs were used in 34 patients) after a median of 7 days from ICH onset. There was neither hematoma expansion nor excessive hemorrhagic complications during hospitalization after starting anticoagulant therapy. CONCLUSIONS: Anticoagulant therapy was conducted for approximately 90% of anticoagulation-indicated patients after a median of 7 days from ICH onset. The predominant anticoagulant medications were DOACs. Anticoagulant therapy started from the acute phase of ICH should be safe.

DOI： 10.1253/circj.CJ-18-0938

PubMed

researchmap

Publishing type：Research paper (scientific journal)  

researchmap

Publishing type：Research paper (scientific journal)  

researchmap

researchmap

Authorship：Lead author   Publishing type：Part of collection (book)  

researchmap

Authorship：Lead author   Publishing type：Part of collection (book)  

researchmap

researchmap

Publishing type：Research paper (scientific journal)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Japanese Circulation Society  

Background: Insufficient anticoagulant intensity on admission is common in stroke patients with atrial fibrillation (AF) on vitamin K antagonist (VKA) therapy. Nevertheless, the effects of VKA under-treatment on stroke severity or arterial occlusion are not well known. The aim of the present study was to investigate the relationship between insufficient VKA therapy and stroke severity, or the site of arterial occlusion in patients with acute ischemic stroke (AIS) and AF. Methods and Results: From March 2011 through July 2016, 446 consecutive patients with AF and AIS were recruited. Of the 446 patients, 364 (167 women
median age, 79 years
IQR, 71–86 years) with anterior-circulation stroke were assessed to investigate the effects of insufficient VKA. Of these, 281 were on no anticoagulant, 53 were undertreated with a VKA, and 30 were sufficiently treated with VKA on admission (PT-INR ≥2.0 for patients &lt
70 years and PT-INR ≥1.6 for ≥70 years old). On multivariate analysis, insufficient VKA was independently associated with severe stroke (i.e., initial NIHSS score ≥10
OR, 2.70, P=0.022) and higher prevalence of proximal artery occlusion (OR, 1.91
P=0.039) compared with no anticoagulant therapy. Conclusions: Insufficient VKA therapy on admission was associated with higher severity of stroke and higher prevalence of proximal artery occlusion in patients with AF and acute anterior-circulation stroke compared with no anticoagulant medication.

DOI： 10.1253/circj.CJ-17-1110

Web of Science

Scopus

PubMed

researchmap

Publishing type：Research paper (scientific journal)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：KARGER  

Background: Thrombus visualization in patients with acute ischemic stroke has been detected and reported using various imaging modalities. T1-weighted imaging (T1-WI) can depict thrombi as hyperintense signals within vessels. Moreover, in addition to thrombi, T1-WI hyperintensities in arteries may suggest arterial dissection. However, the frequency of and factors related to the T1-hyperintense vessel sign (T1-HVS) are not fully known. The aim of this study was to clarify the prevalence of and related factors for the T1-HVS in patients with acute ischemic stroke.
Methods: From September 2014 through December 2015, consecutive acute ischemic stroke patients who were admitted to our stroke unit within 7 days from symptom onset were retrospectively recruited from the prospective registry. A T1-HVS was defined as the presence of a hyperintense signal, with intensity higher than surrounding brain, within the vessel lumen. Moreover, T1-HVSs were separated into filled T1-HVSs (hyperintensity fills whole vessel lumen) and non-filled T1-HVSs. The frequency of the T1-HVS and the timing of emersion and the relationship between the presence of the T1-HVS and arterial occlusion were assessed. Results: A total of 399 patients (139 women; median age 73 years; National Institutes of Health Stroke Scale score 3) were enrolled in the present study. Of these, 327 (82%) patients had T1-WI on admission. Two hundred and sixty-seven (67%) subjects had at least one follow-up T1-WI (median 6 days after admission), and 134 (34%) cases had &gt;= 2 follow-up T1-WI examinations. The T1-HVS was observed in 18 patients during admission; therefore, the frequency of the T1-HVS in acute ischemic stroke patients was 4.5% (95% CI 2.5-6.5%). All but one (94%) of the T1-HVSs were first observed on follow-up imaging, and the median number of days from onset to T1-HVS appearance was 9. For patients having initial major artery occlusion and follow-up MRI (n = 95), sensitivity and specificity of the T1-HVS for persistent arterial occlusion on follow-up MR angiography were 22 and 100%, respectively. T1-HVS persisted for a few months and then normalized. Although there were no significant differences between filled and non-filled T1-HVS, more patients with non-filled T1-HVS had arterial dissection (43%) than those with filled T1-HVS (9%, p = 0.245). Conclusion: The T1-HVS was observed in 4.5% of acute ischemic stroke patients. T1-HVSs appeared in the subacute phase in arteries with persistent occlusion and remained for a few months. (C) 2017 S. Karger AG, Basel.

DOI： 10.1159/000479593

Web of Science

PubMed

researchmap

Authorship：Lead author   Publishing type：Part of collection (book)  

researchmap

Publishing type：Research paper (scientific journal)  

researchmap

Authorship：Lead author  

researchmap

Authorship：Lead author   Publishing type：Part of collection (book)  

researchmap

Authorship：Lead author   Publishing type：Research paper (scientific journal)  

researchmap

Authorship：Lead author  

researchmap

Publishing type：Research paper (scientific journal)  

researchmap

Authorship：Lead author   Publishing type：Research paper (scientific journal)  

researchmap

Authorship：Lead author  

researchmap

Authorship：Lead author  

researchmap

Publishing type：Research paper (scientific journal)  

researchmap

Publishing type：Research paper (scientific journal)  

researchmap

Authorship：Lead author   Publishing type：Part of collection (book)  

researchmap

Authorship：Lead author  

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

researchmap

Authorship：Lead author  

researchmap

Authorship：Lead author   Publishing type：Part of collection (book)  

researchmap

Language：Japanese   Publisher：(一社)日本脳神経超音波学会  

researchmap

Language：Japanese   Publisher：日本内科学会-関東地方会  

researchmap

Presentation type：Symposium, workshop panel (public)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (invited, special)  

researchmap

Presentation type：Oral presentation (invited, special)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Public lecture, seminar, tutorial, course, or other speech  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Public lecture, seminar, tutorial, course, or other speech  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Symposium, workshop panel (nominated)  

researchmap

Presentation type：Symposium, workshop panel (public)  

researchmap